Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Change in Cash: 2010-2025

Historic Change in Cash for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to -$1.8 million.

  • Lineage Cell Therapeutics' Change in Cash rose 3.54% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.7 million, marking a year-over-year increase of 443.02%. This contributed to the annual value of $10.4 million for FY2024, which is 56.93% down from last year.
  • According to the latest figures from Q3 2025, Lineage Cell Therapeutics' Change in Cash is -$1.8 million, which was up 67.70% from -$5.6 million recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Change in Cash ranged from a high of $23.5 million in Q1 2021 and a low of -$46.1 million during Q3 2022.
  • Its 3-year average for Change in Cash is $2.6 million, with a median of $2.0 million in 2025.
  • The largest annual percentage gain for Lineage Cell Therapeutics' Change in Cash in the last 5 years was 7,931.74% (2021), contrasted with its biggest fall of 10,622.92% (2021).
  • Lineage Cell Therapeutics' Change in Cash (Quarterly) stood at -$5.1 million in 2021, then tumbled by 164.52% to -$13.4 million in 2022, then spiked by 129.88% to $4.0 million in 2023, then surged by 352.10% to $18.0 million in 2024, then rose by 3.54% to -$1.8 million in 2025.
  • Its Change in Cash was -$1.8 million in Q3 2025, compared to -$5.6 million in Q2 2025 and $2.0 million in Q1 2025.